MedTrace Logo

The Efficacy of a Smart Phone-based Test on Measuring Pupillary Light Reflex Alterations Following Cannabis Use Healthy in Adults

NCT06967051 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-07-17

No results posted yet for this study

Summary

The goal of this open label study is to evaluate the efficacy of smart phone-based test (SOBEREYE OPTOVERA) on measuring pupillary light reflex (PLR) alterations following cannabis use healthy in adults. The main question it aims to answer is:

Can SOBEREYE OPTOVERA detect PLR alterations following cannabis consumption in healthy adults, in comparison to a pupillometer?

Participants will be given two 5 mg capsules to be ingested for the 10 mg THC dose or five 5 mg capsules to be ingested for the 25 mg THC. Participants will be asked to complete PLR tests throughout the study day.

Conditions

  • Cannabis Intoxication
  • Drug Effects

Interventions

DRUG

Tetrahydrocannabinol (10 mg)

10 mg of Tetrahydrocannabinol (THC) provided as a softgel capsule

DRUG

Tetrahydrocannabinol (25 mg)

25 mg of THC provided as a softgel capsule.

DIAGNOSTIC_TEST

Pupillary Light Reflex (PLR) Test

SOBEREYE OPTOVERA is a portable, non-invasive test that measures the Pupillary Light Reflex (PLR)

DIAGNOSTIC_TEST

Pupillometer

NeuroLight is an automated pupillometer that generates a flash of light and measures the photomotor reflex very accurately.

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • Sobereye Inc.

    lead INDUSTRY

Principal Investigators

  • David Crowley, MD · KGK Science Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2025-08-31
Completion
2025-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06967051 on ClinicalTrials.gov